Kellogg Co. is bringing back Honey Smacks cereal on U.S. retailer shelves in November 2018, months after pulling the product due to a Salmonella scare.
Roche’s Tecentriq plus chemotherapy boosted lung cancer patients’ survival by nearly five months, study data showed, underscoring benefits of the Swiss group’s immunotherapy but still leaving the company trailing a rival’s drug.
An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive.
An experimental cancer drug that Novartis hopes will raise the profile of the company’s oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.
Sanofi SA’s eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma.
An EMA panel recommended approving a potential blockbuster drug from Shire Plc to treat a rare hereditary disease.
Australia’s competition watchdog said the High Court dismissed its special leave application to appeal a court’s decision on whether Pfizer Inc.’s local unit used the company’s market power to limit competition for the cholesterol-lowering drug Lipitor.
The U.S. Food and Drug Administration rejected Novartis’ bid to repurpose canakinumab, a drug already approved for rare inflammatory diseases, for use in a group of heart attack survivors.
U.S. drugmaker AbbVie Inc. said a patent dispute was settled regarding the Humira biosimilar with Fresenius Kabi Oncology Ltd. and will grant the Germany-based company non-exclusive marketing rights for the drug.
Merck & Co.’s cancer drug Keytruda in combination with Pfizer Inc.’s Inlyta met the main goals of a late-stage study for the most common form of kidney cancer.
Novartis is acquiring Endocyte and the nuclear medicine specialist’s experimental prostate cancer treatment PSMA-617.
A respected science journal is to withdraw a much-cited review of evidence on an illness known as chronic fatigue syndrome amid fierce criticism and pressure from activists and patients.
The U.S. Centers for Disease Control and Prevention confirmed 62 cases of acute flaccid myelitis – a rare, polio-like condition that causes weakness in the arms or legs – across 22 states.
Express Scripts Holding – one of the largest U.S. prescription benefits managers – will cover new migraine drugs from Eli Lilly and Amgen, but is excluding a rival medication made by Teva Pharmaceutical Industries after price negotiations with all three manufacturers.
Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States during September 2018, following a recall of much of the drug’s supply.
Minnesota’s attorney general filed a lawsuit accusing Sanofi, Novo Nordisk and Eli Lilly of deceptively raising prices for insulin.
People with restless legs syndrome may be more likely to think about suicide or to actually make plans to take their own lives, compared to people without the condition, a new study suggests.
The U.S. Food and Drug Administration approved Pfizer Inc.’s Talzenna (talazoparib) for an advanced form of breast cancer.
Rival versions of the world’s top-selling drug – AbbVie’s Humira – went on sale in Europe, years ahead of similar cut-price copies being available in the United States.
Johnson & Johnson reported slightly better-than-expected third-quarter 2018 profit and raised the company’s full-year forecast.